Hepatitis C Management in Special Populations

  • Author: Mark S. Sulkowski, MD (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 8/17/18 (What's New)

Summary

  • The AASLD/IDSA (Management Guidelines)[AASLD-IDSA HCV] and EASL (Management Guidelines)[EASL HCV] guideline panels provide recommendations for the use of DAA regimens in the treatment of HCV infection in patients with recurrent HCV infection in posttransplantation settings (Table 12)
  • Drug–drug interactions between HCV therapies and immunosuppressants commonly prescribed in the posttransplantation setting may occur (Table 13)

Action required